GlassScriptPhysician profile
David Michael Armstrong
NPI 1962048793
$4,765.64
in general payments reported to CMS, 2019-2025
18 companies · $837 in 2025
The $837 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $484 · 2022: $297 · 2023: $1,482 · 2024: $1,667 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,985.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,189.09 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,044.76 | 2021-2025 | Otezla, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.60 | 2022-2023 | Ofev |
| Glaxosmithkline, LLC. | $381.24 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $356.44 | 2021-2024 | Nexletol, Nexlizet |
| Phathom Pharmaceuticals, INC. | $238.70 | 2024 | Voquezna |
| Lilly USA, LLC | $192.33 | 2023-2024 | Jardiance, Mounjaro |
| Novo Nordisk INC | $186.18 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $150.19 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $146.46 | 2024-2025 | Nuzyra, Xhance |
| Abbvie INC. | $139.22 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $124.99 | 2023 | |
| Janssen Pharmaceuticals, INC | $75.00 | 2021-2023 | Xarelto |
| Pfizer INC. | $42.71 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $41.05 | 2023-2024 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.03 | 2021 | |
| Gilead Sciences, INC. | $19.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.